Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Item

http://www.wikidata.org/entity/Q42437883

Q42437883

about

Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers Beyond RAS and BRAF: a target rich disease that is ripe for picking Palliative care and end-stage colorectal cancer management: the surgeon meets the oncologist.Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.Biological and molecular effects of small molecule kinase inhibitors on low-passage human colorectal cancer cell lines.Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop NDRG4, a novel candidate tumor suppressor, is a predictor of overall survival of colorectal cancer patients.Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.OCF can repress tumor metastasis by inhibiting epithelial-mesenchymal transition involved in PTEN/PI3K/AKT pathway in lung cancer cells.Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro.Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.Renal cancer-selective Englerin A induces multiple mechanisms of cell death and autophagy.Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037.Targeting mTOR network in colorectal cancer therapy EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.Prospects for MEK inhibitors for treating cancer.Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.The biology and clinical development of MEK inhibitors for cancer.Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies.The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.Synergistic cooperation between ABT-263 and MEK1/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells.Effects of RAL signal transduction in KRAS- and BRAF-mutated cells and prognostic potential of the RAL signature in colorectal cancer Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress.Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas.Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer.Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.Pimasertib, a selective oral MEK1/2 inhibitor: absolute bioavailability, mass balance, elimination route, and metabolite profile in cancer patients.MEK inhibitors under development for treatment of non-small-cell lung cancer.Targeting the mitogen-activated protein kinase pathway in low-grade serous carcinoma of the ovary.

P2860

Q26781362-98BB4B74-6E31-4F13-85C6-A8D4C160A98D Q28066095-7A821EAA-5F0F-4E6C-AA1A-60C313FF742F Q31168985-3E577BA7-E5EE-42BD-81F8-4E17F041B24A Q33439312-102BB02F-7A35-4C65-A6BC-64FA54CB342A Q34278085-03D14C55-25E9-4002-A708-EF779AE10338 Q34441837-F1D66FF9-27B8-4058-98CA-065CC3ABE810 Q35741610-D7FEFCB7-B6D4-4168-9270-FA77ABAC8912 Q35781352-F1ECC8DC-EE4B-4F92-9A8D-3082DC74D0BB Q36086845-A1433F6D-CB8D-408D-878C-C7B32446E1DF Q36310903-B96B64A5-F631-487B-B1E6-6B46249956A8 Q36396095-349038D8-BC03-4E6C-B877-852160E28203 Q36782414-30214AF4-7D15-40C8-8459-3F01A22418BB Q37153397-873992B5-6CE0-48D0-A137-0E13D63BFFB8 Q37245874-2971CAF7-8796-4029-AEF3-DFF6B1F70938 Q37421296-A0B79E2B-CB05-414F-AE60-9EE2DE9710B8 Q37708005-9D6CE970-CFF8-482F-AE1D-F6A5646AA489 Q38160089-5F199D24-36D7-445B-8587-76A4017C2C30 Q38193520-04EE8E2B-ACB9-4532-AF17-16C85A6ED6BB Q38199737-CB94CD0B-05F1-4986-9FEC-27CA2D7962C4 Q38270129-FA986C72-AE34-410F-83DF-F3F9679C1446 Q38390840-8A2F6E12-9D61-4D1F-954D-5826041563DE Q38397326-A0E26492-0AC7-4734-BEDD-6F1C0EE0272D Q38554422-B4CD49F6-601D-4E9E-896E-10C20AC4768E Q38585847-BDE47BA7-0640-415D-8A5C-8EDF9D7EDEC6 Q38794217-E778AA5B-E3B1-477F-916C-5C7F5C89CD85 Q38815323-A086B53B-72D3-43A2-A61F-90FE99D55273 Q38868595-57C9D2AF-33A3-44F1-A9F7-3DFF987E008B Q38946538-2231DA9E-1A0B-46C1-AE70-F7B5B92A6A82 Q39933783-5A1B4983-A218-4B20-A498-6D23E34B3D7B Q41667581-C86A9881-3843-475A-A44C-8A2C9F4DF566 Q42085487-E9203011-2E12-4533-881F-E4CBD980F049 Q43987893-DEFAFCCB-2834-4F02-A4F5-48CEBACB118C Q45383453-22E88B49-457B-4085-BA3A-DFC5D932D7DF Q47318847-98884ADF-8B80-4F94-B509-C76F8E635291 Q51609396-BB065D80-0CC8-413D-83F5-A93162C45419

P2860

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

Item

http://www.wikidata.org/entity/Q42437883

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@en

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@nl

type

Item

label

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@en

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@nl

prefLabel

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@en

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@nl

P1476

Antitumor activity of pimasert ...... g and colorectal cancer cells.

@en

P2093

Anna Capasso

http://www.w3.org/2001/XMLSchema#string

Anna Nappi

http://www.w3.org/2001/XMLSchema#string

Donata Vitagliano

http://www.w3.org/2001/XMLSchema#string

Elena D'Aiuto

http://www.w3.org/2001/XMLSchema#string

Erika Martinelli

http://www.w3.org/2001/XMLSchema#string

Floriana Morgillo

http://www.w3.org/2001/XMLSchema#string

Francesco Merolla

http://www.w3.org/2001/XMLSchema#string

Giulia Martini

http://www.w3.org/2001/XMLSchema#string

Liberato Berrino

http://www.w3.org/2001/XMLSchema#string

Loredana Vecchione

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

Targeting the PI3K signaling pathway in cancer

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

The phosphoinositide 3-kinase pathway

Targeting RAS signalling pathways in cancer therapy

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

P304

2089-2101

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.28236

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

Sabine Tejpar

Raffaele De Palma

Fortunato Ciardiello

P577

2013-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236581249

http://www.w3.org/2001/XMLSchema#string

P698

23629727

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

about

P2860

P2860

Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P921